Published in Cancer J on April 08, 2008
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
Identification of genes conferring resistance to 5-fluorouracil. Proc Natl Acad Sci U S A (2009) 1.92
Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother (2010) 1.19
Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol (2015) 1.17
Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol (2011) 1.04
AEG-1/MTDH/LYRIC in liver cancer. Adv Cancer Res (2013) 1.01
The transcription factor LSF: a novel oncogene for hepatocellular carcinoma. Am J Cancer Res (2012) 0.93
Imaging and Imaging-Guided Interventions in the Diagnosis and Management of Hepatocellular Carcinoma (HCC)-Review of Evidence. Iran J Radiol (2012) 0.91
Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization. Clin Exp Metastasis (2008) 0.88
A multidisciplinary approach to the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2010) 0.84
The efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization for primary hepatocellular carcinoma in a cohort of 487 patients. PLoS One (2014) 0.82
Transcatheter arterial chemoembolization followed by immediate radiofrequency ablation for large solitary hepatocellular carcinomas. World J Gastroenterol (2013) 0.81
GRP78 confers the resistance to 5-FU by activating the c-Src/LSF/TS axis in hepatocellular carcinoma. Oncotarget (2015) 0.79
The role of AEG-1 in the development of liver cancer. Hepat Oncol (2016) 0.78
Combination percutaneous and intraarterial therapy for the treatment of hepatocellular carcinoma: a review. Semin Intervent Radiol (2010) 0.78
Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2010) 0.75
Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation. Cancer J (2016) 0.75
Percutaneous microwave ablation combined with synchronous transcatheter arterial chemoembolization for the treatment of colorectal liver metastases: results from a follow-up cohort. Onco Targets Ther (2016) 0.75
Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology (2014) 2.98
Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol (2006) 2.39
The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol (2003) 1.88
Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol (2005) 1.73
Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol (2007) 1.73
Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A (2004) 1.63
Transcatheter intraarterial therapies: rationale and overview. Radiology (2011) 1.59
Adjunctive use of C-arm CT may eliminate technical failure in adrenal vein sampling. J Vasc Interv Radiol (2007) 1.44
Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol (2003) 1.31
Incidence and management of chyle leaks following pancreatic resection: a high volume single-center institutional experience. J Gastrointest Surg (2008) 1.23
Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience. Radiology (2008) 1.21
Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol (2005) 1.15
Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol (2007) 1.13
Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg (2010) 1.13
Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol (2008) 1.13
Iliac vein compression as risk factor for left- versus right-sided deep venous thrombosis: case-control study. Radiology (2012) 1.12
Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol (2007) 1.07
Positron-emission tomography imaging of the angiotensin II subtype 1 receptor in swine renal artery stenosis. Hypertension (2008) 1.07
Spontaneous renal artery dissection: treatment with coil embolization. J Vasc Interv Radiol (2003) 1.03
Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol (2013) 1.02
Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol (2007) 1.00
Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma. Oncotarget (2012) 0.95
Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology (2012) 0.94
Considerations for implantation site of VX2 carcinoma into rabbit liver. J Vasc Interv Radiol (2008) 0.94
Pre- and postoperative clinical care of patients undergoing interventional oncology procedures: a comprehensive approach to preventing and mitigating complications. Tech Vasc Interv Radiol (2006) 0.92
Three-dimensional rotational angiography: introduction of an adjunctive tool for successful transarterial chemoembolization. J Vasc Interv Radiol (2005) 0.91
Safety and efficacy of CT-guided percutaneous cryoablation for renal cell carcinoma. J Vasc Interv Radiol (2008) 0.91
Drug-eluting particles for interventional pharmacology. Tech Vasc Interv Radiol (2007) 0.91
Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol (2008) 0.90
A comparison of clinical outcomes with retrievable and permanent inferior vena cava filters. J Vasc Interv Radiol (2008) 0.90
Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer (2013) 0.88
Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting. Anticancer Res (2013) 0.87
Multi-visceral resection of pancreatic VIPoma in a patient with sinistral portal hypertension. World J Surg Oncol (2008) 0.86
Chemoembolization of hepatic metastases from ocular melanoma: assessment of response with contrast-enhanced and diffusion-weighted MRI. AJR Am J Roentgenol (2008) 0.86
Prospective analysis of the safety and efficacy of percutaneous cryoablation for pT1NxMx biopsy-proven renal cell carcinoma. Cardiovasc Intervent Radiol (2010) 0.86
C-arm cone-beam computed tomography in interventional oncology: technical aspects and clinical applications. Radiol Med (2014) 0.86
Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer. J Hepatobiliary Pancreat Sci (2009) 0.85
Colonic perforation by a percutaneously displaced biliary stent: report of a case and a review of current practice. J Vasc Interv Radiol (2009) 0.84
Targeted transarterial therapy of Vx-2 rabbit liver tumor with Yttrium-90 labeled ferromagnetic particles using an external magnetic field. Anticancer Res (2007) 0.83
Presumed pulmonary embolism following power-pulse spray thrombectomy of upper extremity venous thrombosis. Cardiovasc Intervent Radiol (2006) 0.82
Modeling of the renal kinetics of the AT1 receptor specific PET radioligand [11C]KR31173. Biomed Res Int (2013) 0.80
Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol (2012) 0.80
Cerebral infratentorial large B-cell lymphoma presenting as Parkinsonism. Tohoku J Exp Med (2010) 0.79
Estimating parsimonious models of longitudinal causal effects using regressions on propensity scores. Stat Med (2013) 0.78
Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization. J Comput Assist Tomogr (2008) 0.78
Lower energy endovenous laser ablation of the great saphenous vein with 980 nm diode laser in continuous mode. Cardiovasc Intervent Radiol (2006) 0.77
Quantification and reduction of reflux during embolotherapy using an antireflux catheter and tantalum microspheres: ex vivo analysis. J Vasc Interv Radiol (2013) 0.77
The Impact of Cancer on the Clinical Outcome of Patients After Inferior Vena Cava Filter Placement: A Retrospective Cohort Study. Am J Clin Oncol (2016) 0.76
Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list. Cardiovasc Intervent Radiol (2010) 0.76
Subtotal splenic embolization is a safe and effective treatment for isolated splenic vascular tumors associated with consumptive coagulopathy. J Pediatr Hematol Oncol (2011) 0.75
Erratum to: C-arm cone-beam computed tomography in interventional oncology: technical aspects and clinical applications. Radiol Med (2015) 0.75
Safety and efficacy of catheter directed thrombolysis in children with deep venous thrombosis. Br J Haematol (2012) 0.75
Percutaneous lung tumor ablation. Tech Vasc Interv Radiol (2013) 0.75
Can ethanol therapies injure the bile ducts? Hepatogastroenterology (2003) 0.75
Fatal reperfusion injury after thrombolysis for phlegmasia cerulea dolens. J Vasc Interv Radiol (2012) 0.75